{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.51","upperLimit":"11.24","value":"11.07"},{"groupId":"OG001","lowerLimit":"5.39","upperLimit":"5.59","value":"5.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"546"},{"groupId":"OG001","value":"542"}],"units":"Participants"}],"description":"The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG000","title":"Abiraterone Acetate + Prednisone (AAP)"},{"description":"Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)","title":"Time to Prostate-specific Antigen (PSA) Progression","type":"SECONDARY","unitOfMeasure":"Months"}